David Dubose
Medical · Atlanta, GANPI 1225190507
Payments from drug & device makers
Across 98 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$421
- Amgen$289
- Novo Nordisk$216
- Abbott$195
- Pfizer$186
- Dexcom, Inc.$132
- plus $499 from 14 others
What the payments were for
- Food & beverage$1,939100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 22 | $421 |
| Amgen(2 entities) | 12 | $289 |
| Novo Nordisk | 12 | $216 |
| Abbott | 10 | $195 |
| Pfizer | 8 | $186 |
| Dexcom, Inc. | 6 | $132 |
| AstraZeneca | 7 | $117 |
| Bayer | 4 | $85 |
| Merck | 5 | $83 |
| GSK | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Phadia US Inc. | 1 | $21 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Exact Sciences | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Medtronic | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$116
How this compares
$1,939 in reported general payments places this provider in the 65th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $51,010 |
| MounjaroTirzepatide | 25 | $25,998 |
| MyrbetriqMirabegron | 19 | $11,174 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,751 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 23 | $5,074 |
| Atorvastatin Calcium | 201 | $1,777 |
| Levothyroxine Sodium | 128 | $1,546 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $1,400 |
| SynthroidLevothyroxine Sodium | 15 | $1,006 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 29 | $872 |
| Gabapentin | 69 | $811 |
| Losartan Potassium | 87 | $787 |
| Amlodipine Besylate | 190 | $740 |
| Pravastatin Sodium | 47 | $713 |
| Metformin Hcl | 64 | $561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $216 | $51,01042 claims |
| Lilly USA, LLCMounjaro | $421 | $25,99825 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $11,17419 claims |
| Boehringer IngelheimSpiriva Respimat | $14 | $8,75113 claims |
| GSKShingrix | $38 | $5,07423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 950 medical providers in Georgia.
Other medical in Atlanta
- Kimberly OrleckAtlanta$727K
- Danna Dennis-CalderAtlanta$87K
- Ferrina ShethAtlanta$49K
- Adriana RuizAtlanta$39K
- Punam PunjaAtlanta$31K
- Adrienne AndersonAtlanta$25K
- Jeremiah RobinsonAtlanta$23K
- Steven SchmittAtlanta$15K
- Taylor WeintraubAtlanta$15K
- Margaret SellersAtlanta$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.